ATA3431: Off-the-Shelf Allogeneic CD19/CD20 Program for B-Cell Hematological and Autoimmune Malignancies

  • ATA3431 CAR T
    • ATA3431 consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD20/CD19 CAR construct
    • The CD20-CD19 binding domains are oriented to optimize potency
    • Dual targeting designed to address antigen escape and tumor variability
    • ATA3431 manufacturing is based on clonally expanded EBV T cells, inherently having lower potential for alloreactivity
    • 1XX signaling domain optimizes expansion and mitigates T-cell exhaustion
    • ATA3431 CAR T cells have been designed for T-cell memory, expansion, and anti-tumor efficacy1
    • Preclinical data have demonstrated early evidence of antitumor activity, long-term persistence, and superior tumor growth inhibition compared to an autologous CD19/CD20 CAR T benchmark1
    • Academic program generated proof-of-principle for an earlier-generation allogeneic CD19 targeted CAR EBV T-cell construct in relapsed/refractory B-cell malignancies after stem cell transplant2
    • IND targeted for 2025
  1. Cha, S et al.  Oral Presentation. ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Treatment of B-Cell Malignancies. TCT 2024.
  2. Curran KJ, et al. ASH 2023


Off-the-shelf allogeneic CD19/CD20 CAR T program progressing toward IND submission in 2025.

  • B-cell malignancies
  • Autoimmune disease

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaboration with Memorial Sloan Kettering Cancer Center.